US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

2.10

-0.0400-1.87%

Post-market: 2.100.00000.00%16:05 EDT

Volume:153.95K

Turnover:325.55K

Market Cap:90.76M

PE:-0.63

High:2.22

Open:2.11

Low:2.07

Close:2.14

Loading ...

Overview Company News Filings

Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $6 From $7

THOMSON REUTERS

Morgan Stanley’s Positive Outlook on Kyverna Therapeutics’ KYV-101 for Lupus Nephritis

Analysts Offer Insights on NA Companies: Viking Holdings Ltd (VIK), Kyverna Therapeutics, Inc. (KYTX) and Amer Sports, Inc. (AS)

institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop

Simply Wall St.

Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo

Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo

Kyverna Therapeutics, Inc. : Wells Fargo Cuts Target Price to $24 From $44

THOMSON REUTERS

Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs

Kyverna Therapeutics anounces patient data on KYV-101

Kyverna Therapeutics Inc - Kyv-101 Demonstrates Robust Safety and Tolerability

THOMSON REUTERS

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of Kyv-101 for Treatment of Lupus Nephritis in Symposium at Acr Convergence 2024

THOMSON REUTERS

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)

Kyverna Therapeutics Advances in Cell Therapy Leadership

Kyverna Therapeutics Q3 EPS $(0.80), Inline

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

THOMSON REUTERS

Kyverna Therapeutics Inc Qtrly Shr Loss $0.80

THOMSON REUTERS

BRIEF-Kyverna Therapeutics Appoints Mert Aktar To Its Board Of Directors

Kyverna Therapeutics Appoints Mert Aktar to Its Board of Directors

THOMSON REUTERS

Press Release: Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KYTX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":2.1,"timestamp":1745611200000,"preClose":2.14,"halted":0,"volume":153952,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"16:05 EDT","volume":1343,"amount":2820.3,"timestamp":1745611509952},"delay":0,"floatShares":17920930,"shares":43218873,"eps":-3.325379,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-25 16:00:00 EDT","open":2.11,"high":2.2185,"low":2.065,"amount":325550.9888,"amplitude":0.071729,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.325379,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.04,"preClose":2.14,"latestTime":"08:47 EDT","volume":3,"amount":6.12,"timestamp":1745585222805},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.1,"latestTime":"16:05 EDT","volume":1343,"amount":2820.3,"timestamp":1745611509952},"volumeRatio":0.5580364909759812,"impliedVol":1.1259,"impliedVolPercentile":0.76},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":17920930,"roa":"-46.93%","roe":"-80.74%","lyrEps":-3.325379,"volumeRatio":0.5580364909759812,"shares":43218873,"dividePrice":0,"high":2.2185,"amplitude":0.071729,"preClose":2.14,"low":2.065,"week52Low":1.78,"pbRate":"0.34","psRate":"321.84","week52High":17.55,"institutionHeld":0,"latestPrice":2.1,"eps":-3.325379,"divideRate":0,"volume":153952,"delay":0,"ttmEps":-3.325379,"open":2.11,"prevYearClose":3.74,"prevWeekClose":1.86,"prevMonthClose":1.93,"prevQuarterClose":1.93,"fiveDayClose":1.86,"twentyDayClose":2.355,"sixtyDayClose":3.24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2484191733","title":"Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $6 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2484191733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484191733?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:37","pubTimestamp":1732102648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2484407191","title":"Morgan Stanley’s Positive Outlook on Kyverna Therapeutics’ KYV-101 for Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484407191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484407191?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:25","pubTimestamp":1732101909,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report) yesterday and set a price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanleys-positive-outlook-on-kyverna-therapeutics-kyv-101-for-lupus-nephritis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanleys-positive-outlook-on-kyverna-therapeutics-kyv-101-for-lupus-nephritis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU1720051017.SGD","BK4585","LU0158827781.USD","LU0106831901.USD","LU1989772923.USD","BK4588","LU0098860793.USD","LU1720051108.HKD","LU0158827948.USD","IE00BKVL7J92.USD","BK4139","BK4504","BK4516","LU0225283273.USD","LU0314104364.USD","LU0320765646.SGD","LU1989772840.SGD","LU1668664300.SGD","LU2089283258.USD","LU1548497426.USD","LU1074936037.SGD","BK4127","LU0267386448.USD","LU2271345857.HKD","LU2089284900.SGD","KYTX","IE00BZ1G4Q59.USD","LU0971096721.USD","LU2028103732.USD","LU2023251221.USD","LU1162221912.USD","LU1363072403.SGD","BK4581","LU0006306889.USD","LU0106261372.USD","LU2357305700.SGD","LU2111349929.HKD"],"gpt_icon":0},{"id":"2484632191","title":"Analysts Offer Insights on NA Companies: Viking Holdings Ltd (VIK), Kyverna Therapeutics, Inc. (KYTX) and Amer Sports, Inc. (AS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484632191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484632191?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:21","pubTimestamp":1732101690,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Viking Holdings Ltd (VIK – Research Report), Kyverna Therapeutics, Inc. (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-viking-holdings-ltd-vik-kyverna-therapeutics-inc-kytx-and-amer-sports-inc-as?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-viking-holdings-ltd-vik-kyverna-therapeutics-inc-kytx-and-amer-sports-inc-as?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NA","KYTX","VIK","BK4141","AS","BK4142","BK4139"],"gpt_icon":0},{"id":"2484452638","title":"institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2484452638","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484452638?lang=en_us&edition=fundamental","pubTime":"2024-11-17 21:14","pubTimestamp":1731849252,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Kyverna Therapeutics implies that they have significant influence over the company's share price. 51% of the business is held by the top 6 shareholders. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. A look at the shareholders of Kyverna Therapeutics, Inc.  can tell us which group is most powerful. With 40% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .And last week, institutional endured the biggest losses as the stock fell by 18%.In the chart below, we zoom in on the different ownership groups of Kyverna Therapeutics.Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.NasdaqGS:KYTX Earnings and Revenue Growth November 17th 2024. The definition o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-investors-kyverna-therapeutics-inc-131412475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","NDAQ","KYTX","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","NQmain","LU2210150020.SGD","TQQQ","QLD","PSQ","QID","IE00B64PRP62.GBP","SQQQ","BK4112","MNQmain","IE00B3QW5Z07.USD",".IXIC","IE00BKPKM429.USD","BK4588"],"gpt_icon":1},{"id":"2483858922","title":"Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2483858922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483858922?lang=en_us&edition=fundamental","pubTime":"2024-11-16 03:22","pubTimestamp":1731698520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 14:22 ET (19:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2483732043","title":"Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2483732043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483732043?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:35","pubTimestamp":1731674116,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $24 from $44 and keeps an Overweight rating on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-24-from-44-at-wells-fargo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-24-from-44-at-wells-fargo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0},{"id":"2483962326","title":"Kyverna Therapeutics, Inc. : Wells Fargo Cuts Target Price to $24 From $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2483962326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483962326?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:13","pubTimestamp":1731669221,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nAZN2MN3G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2483394291","title":"Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2483394291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483394291?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:37","pubTimestamp":1731645429,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc. ( ($KYTX) ) has released its Q3 earnings. Here is a breakdown of the information Kyverna Therapeutics, Inc. presented to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-reports-q3-loss-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-reports-q3-loss-amid-rising-rd-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2483800873","title":"Kyverna Therapeutics anounces patient data on KYV-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2483800873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483800873?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:15","pubTimestamp":1731597337,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-anounces-patient-data-on-kyv-101?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-anounces-patient-data-on-kyv-101?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2483880226","title":"Kyverna Therapeutics Inc - Kyv-101 Demonstrates Robust Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2483880226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483880226?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6CCVBY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2483802257","title":"Kyverna Therapeutics Announces New Patient Data Highlighting Potential of Kyv-101 for Treatment of Lupus Nephritis in Symposium at Acr Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483802257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483802257?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6CCVBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2483670807","title":"Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483670807","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483670807?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596460,"startTime":"0","endTime":"0","summary":"Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis  Treated With KYV-101 Target Dose. KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed. Also at ACR Convergence 2024, Kyverna will present data on next-generation approaches, most notably with a poster on Ingenui-T, the Company's preclinical 3-day manufacturing process using autologous whole blood as starting material. Ingenui-T is designed to improve the patient experience by eliminating apheresis, leading to a potential for improved convenience, access and overall cost reduction. As the poster highlights, drug product from the Ingenui-T process manufactured with whol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACR","CAR","BK4139","SLE","KYTX","BK4022","BK4230","BK4110","BK4077"],"gpt_icon":0},{"id":"2483761518","title":"Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483761518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483761518?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585656,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Kyverna Therapeutics, Inc. (KYTX – Research Report), Mural O...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-mural-oncology-plc-mura-and-copa-holdings-cpa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-kyverna-therapeutics-inc-kytx-mural-oncology-plc-mura-and-copa-holdings-cpa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX","BK4500","BK4008","NA","BK4141","MURA","CPA"],"gpt_icon":0},{"id":"2483865786","title":"Kyverna Therapeutics Advances in Cell Therapy Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2483865786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483865786?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:55","pubTimestamp":1731534945,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc. ( ($KYTX) ) just unveiled an announcement. Kyverna Therapeutics has announced significant progress in its clinical-stage...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-advances-in-cell-therapy-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-advances-in-cell-therapy-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2483021863","title":"Kyverna Therapeutics Q3 EPS $(0.80), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483021863","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483021863?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:39","pubTimestamp":1731533947,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which met the analyst consensus estimate. This is a 96.56 percent increase over losses of $(23.27) per share from the same period last","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41956187/kyverna-therapeutics-q3-eps-0-80-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kyverna Therapeutics Q3 EPS $(0.80), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2483868214","title":"Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868214?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:14","pubTimestamp":1731532443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA4MXTF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2483863531","title":"Kyverna Therapeutics Inc Qtrly Shr Loss $0.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863531?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:14","pubTimestamp":1731532443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA4MXTF6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2477857375","title":"BRIEF-Kyverna Therapeutics Appoints Mert Aktar To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477857375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477857375?lang=en_us&edition=fundamental","pubTime":"2024-10-21 20:45","pubTimestamp":1729514732,"startTime":"0","endTime":"0","summary":"Oct 21 (Reuters) - Kyverna Therapeutics Inc   :   * KYVERNA THERAPEUTICS APPOINTS MERT AKTAR TO ITS BOARD OF DIRECTORSSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2477851660","title":"Kyverna Therapeutics Appoints Mert Aktar to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477851660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477851660?lang=en_us&edition=fundamental","pubTime":"2024-10-21 20:00","pubTimestamp":1729512013,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA9LY6RR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2477851610","title":"Press Release: Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2477851610","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477851610?lang=en_us&edition=fundamental","pubTime":"2024-10-21 20:00","pubTimestamp":1729512000,"startTime":"0","endTime":"0","summary":"Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy. EMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. , a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors. Mr. Aktar has over two decades of biopharmaceutical experience, melding more than a decade of technical leadership in cell and gene therapy with a proven track record in corporate development.\"I am thrilled to join the Board of Directors at this critical time in Kyverna's maturation and growth. CAR T is a powerful modality","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1728619200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2025-04-25","current":-0.72553,"percent":0.94386,"low":-26.836094,"twenty":-10.892017,"median":-3.196968,"eighty":-1.264073,"high":-0.620373,"avg":-6.724403,"sd":7.738838,"marketCap":92488388},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-6.996941,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":531179806},{"date":"2024-06-07","current":-7.68982,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":583780403},{"date":"2024-06-14","current":-8.200961,"twenty":-25.032152,"median":-16.052332,"eighty":-8.699606,"marketCap":622584123},{"date":"2024-06-21","current":-4.560506,"twenty":-24.987544,"median":-15.898773,"eighty":-8.182787,"marketCap":346215409},{"date":"2024-06-28","current":-4.179991,"twenty":-24.930446,"median":-15.76307,"eighty":-7.803407,"marketCap":317328195},{"date":"2024-07-05","current":-4.36173,"twenty":-24.826956,"median":-14.259614,"eighty":-7.683005,"marketCap":331125073},{"date":"2024-07-12","current":-5.457841,"twenty":-24.739524,"median":-13.577524,"eighty":-7.436522,"marketCap":414337494},{"date":"2024-07-15","current":-5.56007,"twenty":-24.730602,"median":-13.28826,"eighty":-7.40699,"marketCap":422098238},{"date":"2024-08-02","current":-4.458278,"twenty":-24.721681,"median":-12.998997,"eighty":-7.379728,"marketCap":338454665},{"date":"2024-08-09","current":-3.873307,"twenty":-24.605701,"median":-11.624103,"eighty":-7.046919,"marketCap":294045964},{"date":"2024-08-16","current":-3.955715,"twenty":-24.550387,"median":-10.892017,"eighty":-5.290869,"marketCap":300302089},{"date":"2024-08-23","current":-4.518382,"twenty":-24.300583,"median":-10.727743,"eighty":-4.552081,"marketCap":343017473},{"date":"2024-08-30","current":-4.558166,"twenty":-24.232778,"median":-10.427767,"eighty":-4.550209,"marketCap":346037753},{"date":"2024-09-06","current":-4.308092,"twenty":-24.091818,"median":-9.970659,"eighty":-4.471909,"marketCap":327053138},{"date":"2024-09-13","current":-3.972766,"twenty":-23.91874,"median":-9.027632,"eighty":-4.36173,"marketCap":301596495},{"date":"2024-09-20","current":-3.932981,"twenty":-23.731387,"median":-8.757535,"eighty":-4.249384,"marketCap":298576215},{"date":"2024-09-27","current":-2.983837,"twenty":-23.401288,"median":-8.2038,"eighty":-4.188739,"marketCap":226520973},{"date":"2024-10-04","current":-2.620093,"twenty":-23.064053,"median":-7.803407,"eighty":-4.107358,"marketCap":198906987},{"date":"2024-10-11","current":-2.585992,"twenty":-21.618758,"median":-7.735255,"eighty":-3.980078,"marketCap":196318176},{"date":"2024-10-18","current":-3.211177,"twenty":-19.474268,"median":-7.570554,"eighty":-3.970492,"marketCap":243779713},{"date":"2024-10-25","current":-2.824699,"twenty":-18.098741,"median":-7.43993,"eighty":-3.926161,"marketCap":214439854},{"date":"2024-10-31","current":-3.023622,"twenty":-17.72781,"median":-7.374617,"eighty":-3.831828,"marketCap":229541252},{"date":"2024-11-08","current":-2.989521,"twenty":-17.672403,"median":-7.116207,"eighty":-3.715421,"marketCap":226952441},{"date":"2024-11-15","current":-1.872701,"twenty":-17.597213,"median":-6.278505,"eighty":-3.207767,"marketCap":207223737},{"date":"2024-11-22","current":-1.556683,"twenty":-17.425798,"median":-5.412407,"eighty":-3.142975,"marketCap":172254731},{"date":"2024-11-29","current":-2.251143,"twenty":-17.188674,"median":-4.774139,"eighty":-3.027032,"marketCap":249100201},{"date":"2024-12-06","current":-1.814179,"twenty":-16.975833,"median":-4.636022,"eighty":-2.984974,"marketCap":200747995},{"date":"2024-12-13","current":-1.740051,"twenty":-16.573007,"median":-4.56385,"eighty":-2.967924,"marketCap":192545389},{"date":"2024-12-20","current":-1.509865,"twenty":-16.354452,"median":-4.538274,"eighty":-2.919045,"marketCap":167074138},{"date":"2024-12-27","current":-1.552781,"twenty":-16.348738,"median":-4.469637,"eighty":-2.836066,"marketCap":171823015},{"date":"2025-01-03","current":-1.529373,"twenty":-16.285886,"median":-4.42582,"eighty":-2.761044,"marketCap":169232719},{"date":"2025-01-10","current":-1.482555,"twenty":-16.158753,"median":-4.36173,"eighty":-2.626913,"marketCap":164052125},{"date":"2025-01-17","current":-1.338201,"twenty":-16.045904,"median":-4.308092,"eighty":-2.550774,"marketCap":148078629},{"date":"2025-01-24","current":-1.322595,"twenty":-15.983052,"median":-4.234207,"eighty":-2.251143,"marketCap":146351764},{"date":"2025-01-31","current":-1.291383,"twenty":-15.904487,"median":-4.202948,"eighty":-1.974139,"marketCap":142898035},{"date":"2025-02-07","current":-1.213354,"twenty":-15.784496,"median":-4.179991,"eighty":-1.846951,"marketCap":134263713},{"date":"2025-02-14","current":-1.186044,"twenty":-15.230253,"median":-4.104819,"eighty":-1.754097,"marketCap":131241700},{"date":"2025-02-21","current":-1.108015,"twenty":-14.458884,"median":-4.025294,"eighty":-1.713911,"marketCap":122607378},{"date":"2025-02-28","current":-1.092409,"twenty":-13.883215,"median":-3.978375,"eighty":-1.612864,"marketCap":120880513},{"date":"2025-03-07","current":-1.01438,"twenty":-13.680373,"median":-3.972766,"eighty":-1.557463,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-13.461819,"median":-3.964176,"eighty":-1.544978,"marketCap":107929030},{"date":"2025-03-21","current":-0.885632,"twenty":-12.929002,"median":-3.924456,"eighty":-1.490358,"marketCap":97999559},{"date":"2025-03-28","current":-0.919716,"twenty":-12.491893,"median":-3.833552,"eighty":-1.429495,"marketCap":101771131},{"date":"2025-04-04","current":-0.667833,"twenty":-11.767663,"median":-3.76816,"eighty":-1.355367,"marketCap":85133388},{"date":"2025-04-11","current":-0.633933,"twenty":-11.317698,"median":-3.708606,"eighty":-1.299966,"marketCap":80811896},{"date":"2025-04-17","current":-0.620373,"twenty":-11.049147,"median":-3.322005,"eighty":-1.283581,"marketCap":79083299},{"date":"2025-04-25","current":-0.72553,"twenty":-10.892017,"median":-3.196968,"eighty":-1.264073,"marketCap":92488388}],"updateTime":1745735004972}}}